Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Surgical Wound Infection 4 Colorectal Neoplasms 4 Neoplasms 3 Sepsis 2 Pancreatic Neoplasms 2 Leukemia, Myeloid, Acute 2 Febrile Neutropenia 2 Triple Negative Breast Neoplasms 1 Solitary Pulmonary Nodule 1 Skin Neoplasms 1 Rectal Neoplasms 1 Pancreatic Fistula 1 Neutropenia 1 Neoplasms, Plasma Cell 1 Multiple Pulmonary Nodules 1 Multiple Endocrine Neoplasia Type 1 1 Melanoma 1 Lung Neoplasms 1 Intestinal Neoplasms 1 Inflammation 1 Infections 1 Glioblastoma 1 Fever 1 Exanthema 1 Emergencies 1 Duodenal Neoplasms 1 Discitis 1 Diarrhea 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 146 Ipilimumab 137 pembrolizumab 122 Cyclophosphamide 78 Interleukin-2 69 aldesleukin 63 Temozolomide 46 trametinib 37 Radiosurgery 37 Vemurafenib 36 fludarabine 34 Biopsy 34 dabrafenib 33 Radiotherapy 33 Blood Specimen Collection 31 fludarabine phosphate 30 sargramostim 27 Bevacizumab 27 Introns 23 Dacarbazine 22 Magnetic Resonance Spectroscopy 21 CTLA-4 Antigen 20 encorafenib 19 cobimetinib 19 binimetinib 19 Specimen Handling 19 Paclitaxel 19 Granulocyte-Macrophage Colony-Stimulating Factor 19 Cisplatin 17 incomplete Freund's adjuvant 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Melanoma × Anti-Bacterial Agents × Clear all

NCT03817125 2024-06-06

MCGRAW

Parker Institute for Cancer Immunotherapy

Phase 1 Completed

14 enrolled 22 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡